Burkitt lymphoma Market

Key Highlights

• According to Orphanet (2021), in Europe and North America BL represents around half of all malignant NHL in children and around 2% in adults. In Europe, the standardized incidence ratio is 1/530,000 for individuals aged between 0 and 14 years and 1/670,000 for individuals aged between 15 and 19 years, and males are affected more than the females.

• According to Graham and Lynch (2021), in children younger than 18 years of age, the incidence is approximately 3-6 cases per 100,000 children annually. The same study also found that Sporadic BL has an annual estimated incidence of 4 per 1 million children less than 16 years of age whereas the incidence is around 2.5 per 1 million in adults. While immunodeficiency-associated variant has an incidence of 22 per 100,000 in the US.

• Burkitt Lymphoma epidemiology is segmented as Total Burkitt Lymphoma Incident Population, Total Burkitt Lymphoma Diagnosed Cases, Burkitt Lymphoma Gender-specific Cases, Burkitt Lymphoma Age-specific Cases and Total Burkitt Lymphoma Treated Cases in the Burkitt Lymphoma market report.

Request for unlock CAGR of Burkitt Lymphoma Market

DelveInsight's "Burkitt Lymphoma Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Burkitt Lymphoma, historical and forecasted epidemiology as well as the Burkitt Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Burkitt Lymphoma market report provides current treatment practices, emerging drugs, Burkitt Lymphoma market share of the individual therapies, current and forecasted Burkitt Lymphoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Burkitt Lymphoma treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Burkitt Lymphoma Market Disease Understanding and Treatment Algorithm

The DelveInsight’s Burkitt Lymphoma market report gives a thorough understanding of Burkitt Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Burkitt Lymphoma (BLis a form of Non-Hodgkin’s lymphoma in which cancer starts in the immune cells called B-cells. It is characterized as an aggressive non-Hodgkin B-cell Lymphoma. Non-Hodgkin’s lymphoma (NHL) is a type of cancer that begins in the lymphatic system, which is a part of body’s germ-fighting immune system. In NHL, white blood cells (WBCs) called lymphocytes grow abnormally and can form growths (tumors) throughout the body. Burkitt Lymphoma often found to be associated with Epstein Barr virus (EBV), human immunodeficiency virus (HIV), and chromosomal translocations that cause the overexpression of oncogene c-myc.

The exact cause of BL is still unknown and the risk factors usually varies as per the geographic locations. Research suggests that BL is the most common in childhood cancers in reigons where there is a high incidence of malaria, like Africa. Elsewhere, the greatest risk factor is HIV.

Symptoms of BL depends on the type for example: Endemic variant usually starts as tumors of jaw or other facial bones and can also affect GI tract, ovaries, bones, and breast. Soradic and immunodeficiency-associated usually starts in bowel and form a bulky tumor mass in the abdomen, often with massive involvement of liver, spleen, and bone marrow. Other symptoms may include loss of appetite, weight loss, fatigue, night sweats, and unexplained fever.

Burkitt Lymphoma Diagnosis

The diagnosis of BL stats with a medical history and physical examination. Also, a biopsy of tumors confirms the diagnosis which is usually done by taking a sample of tissue which is then examined under a microscope. The bone marrow and central nervous system are often involved. Bone marrow and spinal fluid are usually examined to see how far the cancer has spread. Additional diagnostic tests may include: Computed tomographic (CT) imaging of the chest, abdomen, and pelvis, Chest X-ray, PET or gallium scan, bone marrow biopsy, exam of spinal fluid, blood tests to measure kidney and liver function, testing for HIV disease.

There are basically three types of burkitt lymphoma as per classification by the World Health Organization (WHO) i.e., Endemic (African): Primary affects African Children, Sporadic (non-African): It occurs all over the globe, Immunodeficiency-associated: It is most common in people with HIV/AIDS and can also occur in people with congenital conditions that cause immune deficiency and in organ transplant patients who take immunosuppressive drugs.

Burkitt Lymphoma Treatment

Treatment often involves intravenous chemotherapy. Examples of chemotherapeutic drugs may include cyclophosphamide, cytarabine, doxorubicin, etoposide, methotrexate, and vincristine. Other treatment may also include chemotherapy in combination with RITUXAN (rituximab), autologous stem cell transplantation, radiation therapy, and steroidal therapy. In some cases surgery may also be need to remove parts of the intestine that are blocked, bleeding, or have ruptured.

Burkitt Lymphoma Epidemiology

The Burkitt Lymphoma epidemiology section provides insights about historical and current Burkitt Lymphoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• According to Orphanet (2021), in Europe and North America BL represents around half of all malignant NHL in children and around 2% in adults. In Europe, the standardized incidence ratio is 1/530,000 for individuals aged between 0 and 14 years and 1/670,000 for individuals aged between 15 and 19 years, and males are affected more than the females.

• According to Graham and Lynch (2021), in children younger than 18 years of age, the incidence is approximately 3-6 cases per 100,000 children annually. The same study also found that Sporadic BL has an annual estimated incidence of 4 per 1 million children less than 16 years of age whereas the incidence is around 2.5 per 1 million in adults. While immunodeficiency-associated variant has an incidence of 22 per 100,000 in the US.

• The disease epidemiology covered in the report provides historical as well as forecasted Burkitt Lymphoma epidemiology [segmented as Total Incident Population of Burkitt Lymphoma, Total Diagnosed Cases of Burkitt Lymphoma, Gender-specific Cases of Burkitt Lymphoma, Age-specific Cases of Burkitt Lymphoma, and Total Treated Cases of Burkitt Lymphoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Burkitt Lymphoma Epidemiology

This section provides glimpse of the Burkitt Lymphoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Learn more about the evolving epidemiology trends and key developments: Burkitt Lymphoma Epidemiology Forecast

Burkitt Lymphoma Drug Chapters

The drug chapter segment of the Burkitt Lymphoma report encloses the detailed analysis of Burkitt Lymphoma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Burkitt Lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Burkitt Lymphoma Marketed Drugs

RITUXAN (rituximab): Genetech/Biogen

It is a CD20 monoclonal antibody used in the management of different cancer indications, which is the only approved drug that is used in combination with different chemotherapeutic regimens for the treatment of Burkitt Lymphoma. Combination regimens were like R-CODOX-M, which is a combination of six drugs that is Rituximab in combination with Cyclophosphamide, Doxorubicin, Cytarabine, Vincristine, and Methotrexate. Other combination regimens were like R-IVAC and DA-EPOCH-R.

Note: Detailed Current therapies assessment will be provided in the full report of Burkitt Lymphoma

Burkitt Lymphoma Emerging Drugs

ADCT-402 (loncastuximab tesirine), is ADC Therapeutics’ lead antibody drug conjugate (ADC), composed of a humanized monoclonal antibody that binds to human CD19 and is conjugated through a linker to a PBD–dimer toxin. Once bound to a CD19-expressing cell, loncastuximab tesirine-lpyl is internalized into the cell, where enzymes release the PBD-based warhead. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication. This ultimately results in cell death. CD19 is a clinically validated target for the treatment of B-cell malignancies.

Sepantronium bromide is being developed by Cothera biosciences for the treatment of High-grade B-cell Lymphoma, and Burkitt Lymphoma. Sepantronium Bromide is a small-molecule proapoptotic agent with potential antineoplastic activity. Sepantronium bromide selectively inhibits survivin expression in tumor cells, resulting in inhibition of survivin antiapoptotic activity (via the extrinsic or intrinsic apoptotic pathways) and tumor cell apoptosis.

Note: Detailed emerging therapies assessment will be provided in the full report of Burkitt Lymphoma

Burkitt Lymphoma Market Outlook

The goal of treatment of BL is to cure and control the lymphoma for as long as possible, control the symptoms, stop it from spreading it to other parts of the body, and stop its recurrence. The decision of the type of treatment required depends upon the stage of the lymphoma, the symptoms, and how lymphoma, affects everyday’s life, overall health, and LDH in the body.

The overall cure rate for sporadic BL approaches around 90% in pediatric and young adult populations. In pediatric patients with complete surgical resection of the disease, it is recommended that patients receive two cycles of chemotherapy of moderate-intensity (i.e. cyclophosphamide, vincristine, prednisolone, doxorubicin).

Standard chemotherapy regimens, such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) are inadequate in treating adult Burkitt lymphoma, hence current recommendations offered by the NCCN include usage of multi-agent regimens with CNS prophylaxis, like R-CODOX-M, DA-EPOCH-R, and others. Other treatment options include autologous stem cell transplantation, radiation therapy, and steroidal therapy. Although in certain cases, surgery might be required to remove parts of the intestine that are blocked, bleeding, or have ruptured.

At present, the treatment of Burkitt Lymphoma faces major challenges due to delay in diagnosis of patients, and due to a lack of approved therapies. Although, the dynamics of Burkitt Lymphoma market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. Key players such as Jazz Pharmaceuticals, Xencor, ADC therapeutics, Cothera Bio, Merck, Cornerstone Pharmaceuticals and various others are involved in developing therapies for Burkitt Lymphoma.

According to DelveInsight, Burkitt Lymphoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Burkitt Lymphoma is very robust, many potential therapies are being investigated for the treatment of Burkitt Lymphoma, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Burkitt Lymphoma market in the 7MM. Aside from that, the market size of Burkitt Lymphoma may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

• The market growth of Burkitt Lymphoma may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Burkitt Lymphoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Burkitt Lymphoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Burkitt Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of Burkitt Lymphoma.

Burkitt Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Burkitt Lymphoma key players involved in developing targeted therapeutics.

Burkitt Lymphoma Clinical Trial Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Burkitt Lymphoma emerging therapies.

Request for sample pages to learn more about the key trends and developments driving the market growth: Burkitt Lymphoma Market

Reimbursement Scenario in Burkitt Lymphoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Burkitt Lymphoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Burkitt Lymphoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Burkitt Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Burkitt Lymphoma Market Report

• The report covers the descriptive overview of Burkitt Lymphoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Burkitt Lymphoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Burkitt Lymphoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Burkitt Lymphoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global Burkitt Lymphoma market

Burkitt Lymphoma Market Report Highlights

• In the coming years, the Burkitt Lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Burkitt Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Burkitt Lymphoma. The launch of emerging therapies will significantly impact the Burkitt Lymphoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Burkitt Lymphoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Burkitt Lymphoma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Burkitt Lymphoma Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Burkitt Lymphoma Pipeline Analysis
• Burkitt Lymphoma Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Burkitt Lymphoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Burkitt Lymphoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Burkitt Lymphoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Burkitt Lymphoma drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Burkitt Lymphoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Burkitt Lymphoma market size during the forecast period (2019-2032)?
• At what CAGR, the Burkitt Lymphoma market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Burkitt Lymphoma market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Burkitt Lymphoma market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Burkitt Lymphoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Burkitt Lymphoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Burkitt Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Burkitt Lymphoma?
• Out of all 7MM countries, which country would have the highest incident population of Burkitt Lymphoma during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Burkitt Lymphoma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Burkitt Lymphoma in the USA, Europe, and Japan?
• What are the Burkitt Lymphoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Burkitt Lymphoma?
• How many therapies are in-development by each company for Burkitt Lymphoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Burkitt Lymphoma treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Burkitt Lymphoma therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Burkitt Lymphoma and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Burkitt Lymphoma?
• What are the global historical and forecasted markets of Burkitt Lymphoma?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Burkitt Lymphoma market
• Organize sales and marketing efforts by identifying the best opportunities for Burkitt Lymphoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Burkitt Lymphoma market
• To understand the future market competition in the Burkitt Lymphoma market